Trials / Completed
CompletedNCT02266524
Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders
Pharmacokinetics, Safety and Tolerability of Single Oral Doses (0.1, 0.2, 0.4 and 0.8 mg) of Tamsulosin Hydrochloride in Children With Voiding Disorders
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 5 Years – 15 Years
- Healthy volunteers
- Not accepted
Summary
To investigate pharmacokinetics, safety, and tolerability of tamsulosin hydrochloride in children with voiding disorders
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tamsulosin hydrochloride, very low dose | |
| DRUG | Tamsulosin hydrochloride, low dose | |
| DRUG | Tamsulosin hydrochloride, medium dose | |
| DRUG | Tamsulosin hydrochloride, high dose |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2005-04-01
- First posted
- 2014-10-17
- Last updated
- 2014-10-17
Source: ClinicalTrials.gov record NCT02266524. Inclusion in this directory is not an endorsement.